Shares of Cooper Companies, Inc. (The) (NYSE:COO) have been assigned a consensus recommendation of “Buy” from the fourteen analysts that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $260.63.

A number of analysts recently issued reports on the stock. KeyCorp restated a “sector weight” rating on shares of Cooper Companies, Inc. (The) in a report on Friday, July 21st. J P Morgan Chase & Co restated a “hold” rating and set a $235.00 price objective on shares of Cooper Companies, Inc. (The) in a report on Tuesday, September 12th. Stifel Nicolaus raised their price objective on shares of Cooper Companies, Inc. (The) from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Tuesday, September 12th. Oppenheimer Holdings, Inc. restated a “hold” rating and set a $250.00 price objective on shares of Cooper Companies, Inc. (The) in a report on Tuesday, September 12th. Finally, Robert W. Baird restated a “buy” rating and set a $273.00 price objective (up previously from $267.00) on shares of Cooper Companies, Inc. (The) in a report on Tuesday, September 12th.

Cooper Companies, Inc. (COO) traded down 0.14% on Friday, hitting $241.33. 305,294 shares of the stock traded hands. The firm has a market capitalization of $11.81 billion, a PE ratio of 34.61 and a beta of 0.54. The stock has a 50 day moving average of $243.10 and a 200 day moving average of $228.86. Cooper Companies, Inc. has a 52 week low of $158.73 and a 52 week high of $256.39.

Cooper Companies, Inc. (The) (NYSE:COO) last announced its earnings results on Thursday, August 31st. The medical device company reported $2.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.06. Cooper Companies, Inc. (The) had a net margin of 16.45% and a return on equity of 16.00%. The company had revenue of $556.00 million during the quarter, compared to the consensus estimate of $552.32 million. During the same quarter in the prior year, the company posted $2.30 earnings per share. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. Equities research analysts anticipate that Cooper Companies, Inc. will post $9.73 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/cooper-companies-inc-the-coo-receives-average-rating-of-buy-from-brokerages/1613738.html.

In other news, VP Randal Golden sold 1,621 shares of the firm’s stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $243.65, for a total value of $394,956.65. Following the completion of the transaction, the vice president now directly owns 1,731 shares in the company, valued at $421,758.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary S. Petersmeyer sold 3,977 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $244.94, for a total transaction of $974,126.38. The disclosure for this sale can be found here. Insiders sold 14,892 shares of company stock valued at $3,678,270 over the last 90 days. 1.60% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in COO. Mutual of America Capital Management LLC lifted its position in Cooper Companies, Inc. (The) by 19.8% during the first quarter. Mutual of America Capital Management LLC now owns 6,319 shares of the medical device company’s stock valued at $1,263,000 after purchasing an additional 1,046 shares during the last quarter. Mason Street Advisors LLC lifted its position in Cooper Companies, Inc. (The) by 1.4% during the first quarter. Mason Street Advisors LLC now owns 6,763 shares of the medical device company’s stock valued at $1,352,000 after purchasing an additional 95 shares during the last quarter. Pacer Advisors Inc. lifted its position in Cooper Companies, Inc. (The) by 3.8% during the first quarter. Pacer Advisors Inc. now owns 848 shares of the medical device company’s stock valued at $170,000 after purchasing an additional 31 shares during the last quarter. Nordea Investment Management AB lifted its position in Cooper Companies, Inc. (The) by 24.1% during the first quarter. Nordea Investment Management AB now owns 2,082 shares of the medical device company’s stock valued at $416,000 after purchasing an additional 404 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Cooper Companies, Inc. (The) by 81.3% during the first quarter. JPMorgan Chase & Co. now owns 214,781 shares of the medical device company’s stock valued at $42,933,000 after purchasing an additional 96,317 shares during the last quarter. Institutional investors and hedge funds own 95.79% of the company’s stock.

About Cooper Companies, Inc. (The)

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.